Glenmark's subsidiary Ichnos Sciences enters pact with Almirall for novel drug to treat autoimmune diseases

Under the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news